While prostate-specific antigen (PSA) is frequently employed as a biomarker for PCa diagnosis and prognosis, clinically significant PCa cannot be consistently differentiated from prostatitis or benign prostatic hyperplasia (BPH) due to limited sensitivity and specificity of PSA detection, which leading to over diagnosis and overtreatment [4, 5]. The gene discussed is KLK3; the disease is medical procedure.